Trastuzumab deruxtecan trials for Breast cancer

All Trastuzumab deruxtecan trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Trastuzumab deruxtecan for Breast cancer

• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
  NCT07060807 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 199 locations
• A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
  NCT06832202 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
  NCT06643585 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
  NCT06210776 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
  NCT05376878 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
  NCT06331169 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Basket Study for Oligo-metastatic Breast Cancer
  NCT05982678 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 105 locations
• DESTINY Breast Respond HER2-(Ultra)Low Europe
  NCT05945732 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 216 locations
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
  NCT07198724 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
  NCT06551220 · Phase: Not specified · Ages: 18 Years to 80 Years · Sex: Female · 26 locations
• Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
  NCT07582887 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
  NCT05704829 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 44 locations
• Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
  NCT07393425 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Organoid-based Functional Precision Therapy for Advanced Breast Cancer
  NCT06102824 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
  NCT06429761 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
  NCT06727227 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• Scalp Cooling in MBC
  NCT04986579 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
  NCT06409390 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• TRUDI: TDXD+Durva in HER2+/Low IBC
  NCT05795101 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 3 locations
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
  NCT07137416 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
  NCT05950945 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
  NCT04553770 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
  NCT05900206 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Trastuzumab Deruxtecan in Advanced Breast Cancer
  NCT07180264 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trial of Trastuzumab Deruxtecan in Previously Treated HER2
  NCT06750484 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations

Common questions

How many trials study Trastuzumab deruxtecan for Breast cancer?

27 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.